ASLAN Pharmaceuticals Ltd Overview
Pro stress-test →ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study.
Strategic Profile
Pro stress-test →ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, the company is headquartered in Singapore and has offices in Taiwan and China.
Competitive Landscape
Pro stress-test →In atopic dermatitis, ASLAN competes with established biologics including Dupilumab (Sanofi/Regeneron) and Tralokinumab (Eli Lilly). The IL-13 receptor targeting approach differentiates eblasakimab from current therapies. In alopecia areata, early-stage competitors include JAK inhibitors and other immune modulators under development.
Industry Context
ASLAN Pharmaceuticals Ltd operates in Immunology Drugs.
Key facts
Founded: 2009 · Headquarters: Singapore, Singapore · Employees: 44 · Revenue: $9.1M